Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Edge Therapeutics (EDGE) Share Price

News stories about Edge Therapeutics (NASDAQ:EDGE) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Edge Therapeutics earned a news impact score of 0.16 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.3282921841741 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

Shares of Edge Therapeutics (EDGE) opened at $9.45 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 8.34 and a quick ratio of 8.34. Edge Therapeutics has a 12 month low of $7.30 and a 12 month high of $13.40. The company has a market cap of $288.53, a price-to-earnings ratio of -6.06 and a beta of 2.52.

Edge Therapeutics (NASDAQ:EDGE) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.37) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.11. sell-side analysts anticipate that Edge Therapeutics will post -1.7 earnings per share for the current year.

A number of research firms have recently commented on EDGE. BidaskClub lowered shares of Edge Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, December 12th. Zacks Investment Research raised shares of Edge Therapeutics from a “sell” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Monday, November 6th.

In related news, insider Brian A. Leuthner sold 7,500 shares of the stock in a transaction on Tuesday, December 5th. The shares were sold at an average price of $9.86, for a total transaction of $73,950.00. Following the transaction, the insider now directly owns 95,236 shares of the company’s stock, valued at $939,026.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Brian A. Leuthner sold 2,500 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $10.81, for a total transaction of $27,025.00. Following the transaction, the chief executive officer now directly owns 110,236 shares in the company, valued at $1,191,651.16. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,861 shares of company stock worth $378,035. 36.19% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: This story was first published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at

About Edge Therapeutics

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Insider Buying and Selling by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit